Ontology highlight
ABSTRACT:
SUBMITTER: Davies SM
PROVIDER: S-EPMC2265447 | biostudies-literature | 2008 Mar
REPOSITORIES: biostudies-literature
Davies Stella M SM Borowitz Michael J MJ Rosner Gary L GL Ritz Kristin K Devidas Meenakshi M Winick Naomi N Martin Paul L PL Bowman Paul P Elliott James J Willman Cheryl C Das Soma S Cook Edwin H EH Relling Mary V MV
Blood 20080108 6
Minimal residual disease (MRD) as a marker of antileukemic drug efficacy is being used to assess risk status and, in some cases, to adjust the intensity of therapy. Within known prognostic categories, the determinants of MRD are not known. We measured MRD by flow cytometry at day 8 (in blood) and at day 28 (in bone marrow) of induction therapy in more than 1000 children enrolled in Pediatric Oncology Group therapy protocols 9904, 9905, and 9906. We classified patients as "best risk" if they had ...[more]